Vendor Handover: Protecting Participant Continuity When Home Trial Provision Changes

A vendor handover needs to preserve the relationships, routines and support that make participation possible.

Idea in Brief

The problem: Participants in home trials are often very poorly. They need comfort, stability and confidence in the team working with them. Any disruption is a big challenge. The importance of the same nurse visiting them cannot be underestimated.

The consequences: Disruptions can lead to lost visits, protocol deviation and, in worst case, drop-outs, which impact study outcomes and data integrity.

The remedy: Identify activities at risk first. Preserve suitable existing teams, establish readiness and maintain clear ownership through the handover and early delivery.

A participant may know little about the organisations behind a home trial visit. But they know the nurse who comes to their home and the site team they turn to with concerns.

Overtime, those relationships often become part of the support structure participants and families rely on while managing, for example, a rare disease.

Despite change is part of our industry, for participants, a break in trial delivery may be difficult to accommodate. Some have very limited treatment options and are taking part in the hope of accessing a treatment that could help them. Others depend on home visits to make continued participation less burdensome.

At FutureMeds @home, our commitment to continuity begins with respecting those relationships and understanding what sustains them. And we firmly believe that commitment to continuity needs to shape the decisions made throughout a study and especially a vendor handover.

1. Identify where continuity is most exposed

The first assessment should establish which services remain available and which services need vendor considerations, for example, due to geographic coverage.

The sponsor or CRO coordinating the transition should work with sites to identify:

• Clinical priorities: activities needed for treatment or safety decisions, with clinical assessment led by the investigator.

  
  

• Time-sensitive requirements: visits or assessments with limited scope for rescheduling.

  
  

• Participant constraints: circumstances that make an alternative arrangement difficult to use.

This creates a basis for deciding where attention and resources are needed first.

A return to the site may be suitable only for a small portion of participants. Homecare Visits are often the only option for patients to participate in a clinical trial. The obligation to return to sites for the visit will often expose the participants and caregiver to the choice to discontinue with the study or accept significant burden and extra effort to continue with the study.

The sponsor will have to be prepared for decreasing compliance and an increased dropout rate.

2. Preserve the support around familiar people

Existing nurses and coordinators hold knowledge worth carrying forward: how a participant prefers to communicate, when a family member needs to be present and which arrangements make a visit manageable. And we can’t forget about well-established communication flows and kind of a routine between participant, nurse and caregiver.

Where a provider uses subcontracted nursing organisations or local partners, some of those relationships may be preserved. The assessment should establish who delivers each activity and what they would need to continue under agreed arrangements.

Keeping the same people requires attention to the services around them.

Research from Cambridge and Tufts on decentralised trials describes how changing one part of delivery can introduce demands elsewhere. It is a useful lens to look through when assessing an existing nursing partner’s ability to continue.

For instance, consider an illustrative scenario: the local nursing organisation remains available, allowing a participant to keep their usual nurse. However, scheduling and access to visit documentation were managed by the outgoing provider. The next visit still depends on establishing how the nurse receives instructions, records findings and reaches the investigator.

Retaining a delivery partner and recruiting individual staff are also different options. Each needs a realistic assessment of availability, qualification, agreements and oversight.

Here’s an example from Jakob Ettinger, Head of Project Management and Decentralised Logistics

“On a paediatric rare disease study our nurses were taking care of participants for 2+years when the sponsor decided to change the global vendor for the study. At this stage, the relationship between the Homecare Nurses, the participants and their caregivers was already so strong that they were seriously considering dropping out of the study. Keeping FutureMeds @home and our homecare nurses as the Local Vendor helped the participants and their families navigate the global vendor change with minimal administrative burden.

All participants stayed till the remainder of the study, more than 12 months, without interruption.”

But if personnel should change, relevant knowledge should move through an authorised, secure handover. A planned introduction can help participants and families understand who will support them and where to take questions. Put yourself in their shoes. What would make you feel more confident about the future of the trial?

3. Confirm readiness at both service and visit level

A proposed start date needs to reflect two sets of dependencies:

• Across the service: appropriate agreements, provider qualification, oversight arrangements and authorised access to information and systems.

  
  

• For each visit: a suitably prepared professional, the required materials and logistics, participant confirmation and a clear route to the investigator.

The bare minimum for the responsible teams to establish what changes to trial documentation, participant information, notifications or approvals are needed for the particular study and country. European recommendations emphasise sponsor and investigator oversight and recognise national differences in decentralised trial arrangements.

For each dependency, record what is confirmed, the evidence supporting that judgement and any remaining action, owner and deadline. Agree who confirms readiness for the relevant activities.

Some transitions will have limited overlap or information arriving in stages. Missing information needs to be visible and escalated so the responsible study team can assess interim arrangements. Where different parts of the service become ready at different times, a phased transition may merit consideration.

We’d also need to emphasise here the importance of experience in running clinical both at site and at home especially in a DCT setting where clinical study conduct is critical. Let it be about the crucial role of out of window visit, or how to ensure PI oversight and protect PI confidence with a change, how to communicate with the sites and PIs.

4. Carry unfinished work through the vendor handover

A provider’s final visit may leave results to review, documentation to complete or a participant concern requiring follow-up.

If there’s room for this, the sponsor and the previous vendor should agree on the open action plan for the activities which have been started by the previous vendor and need to be completed by the new vendor. It is one better, if the new vendor could get access to meeting minutes with sponsor and issues logs to learn the history and identify actions.

The transition plan should therefore establish proper Transition Governance with clear responsibilities and timelines, appointment of dedicated resources, and step by step roadmap, including client communication, process and communication flows, as well relationship rules moving forward, study specific transition plans focused on patients, study outcomes, systems and data flows transfer, transition risks and contingency arrangements, and any risks and challenges experienced so far.

Our team at FutureMeds @home often been relied on to take over studies form other vendor due various reasons. We know how to manage the process and how to ensure study continuity, while ensuring a good transition for sites, patients, caregivers, nurses, as well all other stakeholders involved into the study such as equipment vendors, logistics, labs.

5. Check what continuity means in practice

The early review should combine delivery evidence with participant and site feedback. Some useful questions include:

• Did visits take place within the required windows, and what explains any changes?

  
  

• Are results, documentation and follow-up reaching the right people?

  
  

• Have new arrangements created additional travel, repeat visits or coordination work for families and sites?

Clinical postponements and participant choices need to be understood separately from service failures. Participants should also know who is coming to their home, whom to contact and what to expect next.

At FutureMeds @home, protecting continuity means keeping those individual experiences central while addressing the operational work behind them. The relationships participants and families have built deserve careful consideration in every decision about how their trial support continues.

If your organisation is managing a vendor change, come talk to our operations team to take advantage of our teams' 15+ years' experience. Use this opportunity to stress test your study- and TA-specific transition options.

Gemma Whiteley is Managing Director of FutureMeds @Home, where she leads the delivery of decentralized and home-based clinical trial services across Europe.